Seretide Competition Builds Up But Substitutability Holds Key?
This article was originally published in Scrip
Executive Summary
More possible competition is building for GlaxoSmithKline's blockbuster salmeterol and fluticasone combination, with a second Indian firm teaming up with the Polish biopharmaceutical company Celon to produce a version of the product.
You may also be interested in...
Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'
Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.
Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'
Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.
Can Glenmark-Celon’s Generic Seretide DPI Break Into Germany?
Glenmark-Celon’s generic version of GlaxoSmithKline’s Seretide Accuhaler dry powder inhaler (DPI) has received the go ahead in Germany, upping the competition quotient in a significant market that has generally been seen as tough to penetrate.